exacerbations – Medxy AI

Defining and Achieving Disease Stability in COPD: Insights from Phase 3 Trials

By MedXY 09/09/2026

This article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.

news Respiratory

Comparative Efficacy of Mepolizumab and Dupilumab in Eosinophilic COPD: Insights from a Matching-Adjusted Indirect Treatment Comparison

By MedXY 08/23/2026

A recent MAIC study comparing mepolizumab and dupilumab in eosinophilic COPD patients found no significant difference between the treatments in reducing exacerbations or improving quality of life.

news Respiratory

Refining COPD Exacerbation Risk Categories Enhances Prediction of Future Episodes

By MedXY 08/20/2026

A recent study demonstrates that defining COPD exacerbation risk by any moderate or severe event over two years improves prediction accuracy and clinical decision-making compared to the standard one-year criteria.

Allergy & Immunology Neurology news

Inebilizumab Significantly Reduces Exacerbations and Need for Rescue Therapy in Generalized Myasthenia Gravis: Insights from the Phase 3 MINT Trial

By MedXY 08/14/2026

The MINT trial demonstrates that inebilizumab markedly lowers exacerbation rates and rescue therapy use in AChR+ and MuSK+ generalized myasthenia gravis patients undergoing corticosteroid tapering.

news Respiratory

Mepolizumab and Blood Eosinophil Variability in COPD: A New Dimension in Targeted Therapy

By MedXY 06/13/2026

This article reviews mepolizumab efficacy in COPD patients with variable blood eosinophil counts, showing benefits even with intermittent eosinophilia, expanding treatable phenotypes beyond persistent elevation.

Allergy & Immunology news Respiratory

Twice-Yearly Depemokimab Maintained Asthma Control After Switching From Mepolizumab or Benralizumab, but Did Not Meet Formal Noninferiority for Exacerbations

By MedXY 05/29/2026

In the phase 3A NIMBLE trial, switching biologic-responsive severe asthma patients to twice-yearly depemokimab preserved overall control and showed comparable safety, but formal noninferiority versus continued mepolizumab or benralizumab for exacerbations was not achieved.

Cardiology news Respiratory

A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD

By MedXY 05/11/2026

COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve survival rates.

Internal Medicine news Respiratory

Mild and Single Moderate COPD Exacerbations Predict Future Risks: Insights from a Community-Based Cohort Study

By MedXY 04/27/2026

Community-based COPD patients with mild or single moderate exacerbations show higher future exacerbation risks and lung structural abnormalities, despite stable lung function decline rates.

news Respiratory

Mepolizumab in Preventing COPD Exacerbations in Patients with Eosinophilic Phenotype: Insights from the MATINEE Trial

By MedXY 09/19/2025

Mepolizumab significantly reduces moderate to severe COPD exacerbations in patients with elevated eosinophils on triple inhaled therapy, marking a promising advance for eosinophilic COPD management.

news Respiratory Specialties

Targeting IL-33 in COPD: Insights from the Phase 2a FRONTIER-4 Trial of Tozorakimab

By MedXY 09/19/2025

The FRONTIER-4 phase 2a trial evaluated tozorakimab, an anti-IL-33 monoclonal antibody, in moderate-to-severe COPD with chronic bronchitis. While the primary endpoint was unmet in the overall population, efficacy signals emerged in patients with frequent exacerbations, supporting ongoing phase 3 studies.

news Respiratory Specialties

Evaluating Carbocysteine in Mild-to-Moderate COPD: Insights From a Large Multicenter Controlled Trial

By MedXY 09/10/2025

A large phase 4 trial found carbocysteine did not significantly reduce exacerbation rates or improve lung function in mild-to-moderate COPD, suggesting limited benefit beyond severe cases.